Rangarajan Subhashree, Friedman Simon H
Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 5005 Rockhill Road, Kansas City, MO 64110, USA.
Bioorg Med Chem Lett. 2007 Apr 15;17(8):2267-73. doi: 10.1016/j.bmcl.2007.01.070. Epub 2007 Jan 27.
We are targeting molecules to the RNA/DNA heteroduplex that forms during the enzyme telomerase's catalytic cycle. Telomerase is a potential universal anti-cancer target that we have previously shown can be inhibited by molecules that target this heteroduplex. The aim of this work was to make derivatives of our lead, ethidium, that would allow its straightforward incorporation into molecules in both solid and solution phase. The heteroduplex targeting intercalator will act as a scaffold to allow the incorporation of new functionalities that will interact with specific protein surfaces of telomerase, thereby potentially increasing affinity and specificity. In examining multiple new derivatives of ethidium, with literature precedent or novel, we have identified one, a 5-benzylic acid ethidium derivative that is synthesized in three steps as a single isomer, and completely retains the inhibition efficacy of the parent compound. Furthermore, we have demonstrated that it can be effectively incorporated into resin bound amines on the solid phase. As such it represents an ideal monomer for the exploration of telomerase inhibition or for other applications which would benefit from hybrid molecules that can target duplexes.
我们将分子靶向于在端粒酶催化循环过程中形成的RNA/DNA异源双链体。端粒酶是一个潜在的通用抗癌靶点,我们之前已经表明,靶向这种异源双链体的分子可以抑制端粒酶。这项工作的目的是制备我们的先导化合物乙锭的衍生物,使其能够直接掺入固相和溶液相的分子中。靶向异源双链体的嵌入剂将作为一个支架,以便掺入能够与端粒酶特定蛋白质表面相互作用的新功能基团,从而有可能提高亲和力和特异性。在研究乙锭的多个新衍生物(有文献先例的或新颖的)时,我们鉴定出了一种,即5-苄基酸乙锭衍生物,它通过三步合成,为单一异构体,并且完全保留了母体化合物的抑制效力。此外,我们已经证明它可以有效地掺入固相上与树脂结合的胺中。因此,它是探索端粒酶抑制作用或用于其他受益于能够靶向双链体的杂合分子的应用的理想单体。